Von Willebrand factor human

Generic Name: Von Willebrand factor human

Brand Names: Vonvendi, Wilate

Drug Type: Biotech

CAS Number: 109319-16-6

Unique Ingredient Identifier: ZE22NE22F1

Background: The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII). Exogenous sources of vWF are used to restore functional levels of vWF in blood disorders associated with deficient or abnormal blood clotting. The human vWF is used to manage and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It was first approved by the FDA in 2015. As vWF is normally present in the blood as a stable complex with coagulation factor III, therapeutic vWF products are also available as a combination product with antihemophilic factor human. A recombinant form of vWF, vonicog alfa, is also available to enhance production and avoid the theoretical risk of pathogen transmission from plasma donors.

Indication: The von Willebrand factor (vWF) is indicated to manage and control bleeding episodes in adults with von Willebrand disease. It is also used for perioperative management of bleeding in these patients. It is also used for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy.

In combination with antihemophilic factor human, vWF is also used to manage and control bleeding associated with von Willebrand disease in children and adults, as well as for perioperative management of bleeding in these patients. This combination product is also used for the management and control of bleeding episodes in adolescents and adults with hemophilia A, as well as for routine prophylaxis to reduce the frequency of bleeding episodes.

Associated Conditions: Bleeding, Perioperative Blood Loss

Associated Therapies: Perioperative bleeding management therapy

Clinical Trials

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Drug: wilate

First Posted Date: 2021-07-08

Last Posted Date: 2024-12-18

Lead Sponsor: Octapharma

Target Recruit Count: 12

Registration Number: NCT04953884

Locations: 🇲🇰
PHI University Clinic for Child Diseases, Skopje, North Macedonia
🇷🇺
FSBI National Research Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇺🇦
Danylo Halytsky Lviv National Medical University, Communal Institution of Lviv Regional Council "Western Ukrainian Specialized Children's Medical Centre", Lviv, Ukraine

and more 6 locations

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

Phase 4

Recruiting

Conditions: Bleeding

Interventions: Other: Placebo
Drug: Wilate

First Posted Date: 2020-09-21

Last Posted Date: 2024-12-11

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 120

Registration Number: NCT04555785

Locations: 🇨🇭
University Hospital Basel, Basel, Switzerland

Effectiveness and Tolerability of Eqwilate in Real-life Conditions

Active, not recruiting

Conditions: VWD - Von Willebrand's Disease

Interventions: Biological: Eqwilate

First Posted Date: 2019-09-27

Last Posted Date: 2025-04-18

Lead Sponsor: Octapharma

Target Recruit Count: 38

Registration Number: NCT04106908

Locations: 🇫🇷
Caen Study Site, Caen, France
🇫🇷
Clamart Study Site, Clamart, France
🇫🇷
Paris Study Site - Lariboisiere, Paris, France

and more 6 locations

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Phase 3

Completed

Conditions: Von Willebrand Diseases

Interventions: Drug: Wilate

First Posted Date: 2019-08-12

Last Posted Date: 2023-10-25

Lead Sponsor: Octapharma

Target Recruit Count: 43

Registration Number: NCT04052698

Locations: 🇧🇾
Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
🇺🇦
State Institution "National Children's Specialized Hospital "OKHMATDYT" of the Ministry of Health of Ukraine," Center of Hemostasis Pathology, Kyiv, Ukraine
🇧🇬
"Specialized Hospital for Active Treatment of Haematological Diseases" EAD, Sofia, Sofia, Bulgaria

and more 11 locations

Von Willebrand Factor Concentrate During ECMO Support

Phase 2

Conditions: Acquired Von Willebrand Disease

Interventions: Drug: Saline Solution
Drug: Von Willebrand Factor

First Posted Date: 2018-08-03

Last Posted Date: 2020-03-12

Lead Sponsor: Tirol Kiniken GmbH

Target Recruit Count: 68

Registration Number: NCT03613584

Locations: 🇦🇹
Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine, Innsbruck, Austria
🇦🇹
Medical University Innsbruck / Department for General and Surgical Critical Care Medicine, Innsbruck, Austria

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: Wilate

First Posted Date: 2017-12-18

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 11

Registration Number: NCT03376516

Locations: 🇷🇺
Kirov SSC Hematology and Transfusiology, Kirov, Russian Federation
🇺🇦
"National Children's Specialized Clinic "OKHMATDYT", Kyiv, Ukraine
🇺🇦
"Western Ukrainian Specialized Children's Medical Center", Lviv, Ukraine

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

Terminated

Conditions: Hemophilia A

Interventions: Drug: Wilate or Nuwiq

First Posted Date: 2017-11-17

Last Posted Date: 2024-08-09

Lead Sponsor: Octapharma

Target Recruit Count: 14

Registration Number: NCT03344003

Locations: 🇨🇦
Stollery children's hospital, University of Alberta, Edmonton, Alberta, Canada
🇨🇦
Hamilton Health Science center, Toronto, Ontario, Canada
🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

INdividualized ITI Based on Fviii(ATE) Protection by VWF

Phase 4

Terminated

Conditions: Hemophilia A With Inhibitor
Hemophilia A

Interventions: Drug: Wilate

First Posted Date: 2017-07-02

Last Posted Date: 2020-05-29

Lead Sponsor: University of California, Davis

Target Recruit Count: 1

Registration Number: NCT03204539

Locations: 🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Drug: Wilate

First Posted Date: 2016-11-03

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 57

Registration Number: NCT02954575

Locations: 🇧🇬
Specialized Hospital for Active Treatment "Joan Pavel", Sofia, Bulgaria
🇭🇺
National Haemophilia Centre, Budapest, Hungary
🇵🇱
Korczowski Bartosz Gabinet Lekarski, Rzeszow, Poland

and more 4 locations

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

Completed

Conditions: Type 3 Von Willebrand's Disease

Interventions: Drug: Von Willebrand Factor

First Posted Date: 2015-06-02

Last Posted Date: 2024-12-27

Lead Sponsor: Fondazione Angelo Bianchi Bonomi

Target Recruit Count: 265

Registration Number: NCT02460458

Locations: 🇮🇷
Seid-ol-Shohada Hospital - Hemophilia Center - Esfahan University of Medical Science, Esfahan, Iran, Islamic Republic of
🇮🇷
Hemophilia- Thalassaemia Center of Mashhad (Sarvar Clinic) - Mashad University of Medical Science, Mashhad, Iran, Islamic Republic of
🇮🇷
Iranian Hemophilia Comprehensive Treatment Centre - Iranian Hemophilia Society, Tehran, Iran, Islamic Republic of

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy